The Week in Review: A Week of Collaborations in China
June 28, 2008 at 15:35 PM EDT
Last week witnessed the formation of an unusually high number of partnerships involving China. WuXi PharmaTech will partner with Covance on WuXi's Suzhou toxicology lab; the US and China will apply scientific research methods to traditional Chinese medicines; Pacific Biopharma combines three entities in a JV that will manufacture small batches of biological drugs; Krka invested in two China pharmaceutical companies; BioAlliance Pharma sold the China rights for Loramyc™ to NovaMed Pharma; Oculus will use Bayer (Sichuan) to gain approval of Microcyn in animals; Microbix Biosystems and the Hunan government will build a large vaccine facility; Yunnan Baiyao Group bought the remaining 49% of Lijiang Medicine Co.; Bayer AG expects to be the biggest seller of prescription drugs in China this year; and we published a report from the BIO convention on VC investment in Asia. More details... Stock Symbols: ( NYSE: WX ) ( NYSE: CVD ) (Euronext Paris: BIO) ( NSDQ: OCLS ) ( Toronto: MBX ) (SZSE: 0005380) (FSE: BAYA)
